Large employers anticipate a 9% rise in healthcare costs for 2026, with pharmacy spending claiming an increasingly significant portion of that budget. Despite this mounting financial pressure, the decision-making process is typically scattered across HR departments, finance teams, external brokers, and consultants. Paul Pruitt, Chief Growth Officer at SHARx, describes this as an accountability gap where no single entity is tasked with delivering measurable value.
The Accountability Gap Driving Corporate Pharmacy Costs
Pharmacy benefits have emerged as a primary driver of corporate healthcare expenses, yet the responsibility for these costs remains dangerously fragmented. According to SHARx, this lack of clear ownership prevents organizations from moving beyond passive budget absorption toward effective, outcome-based management of their prescription drug spending.
The Failure of Traditional Oversight
Market concentration further complicates the issue. The Federal Trade Commission reported that the top three pharmacy benefit managers—CVS Caremark, Express Scripts, and OptumRx—processed nearly 80% of U.S. prescriptions in 2023. While McKinsey data indicates that 79% of large employers are attempting to manage drug costs through various methods, these efforts often result in what Pruitt calls "oversight theater." Audits confirm contract compliance but rarely address whether the underlying system serves the employer's best interest. For many organizations, the reflexive response remains shifting costs to employees or switching vendors, neither of which disrupts the core economic model of the pharmacy supply chain. True control, Pruitt argues, requires treating pharmacy benefits as a strategic governance priority with defined performance standards rather than a routine line item.
Comments (0)
No comments yet. Be the first!